相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical89Zr-immuno-PET
Marion Chomet et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab′)2 Fragments of Obinutuzumab in Lymphoma
Lei Kang et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Detecting TRA-1-60 in Cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent
Jordan M. White et al.
MOLECULAR PHARMACEUTICS (2020)
Preparation of Zirconium-89 Solutions for Radiopharmaceutical Purposes: Interrelation Between Formulation, Radiochemical Purity, Stability and Biodistribution
Anton Larenkov et al.
MOLECULES (2019)
Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab
Morgane Agez et al.
SCIENTIFIC REPORTS (2019)
Fully Automated 89Zr Labeling and Purification of Antibodies
Alex J. Poot et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Site-specifically labeled 89Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model
Lotte K. Kristensen et al.
THERANOSTICS (2019)
Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts
Jason T. Yoon et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies
Christopher G. England et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Understanding Changes in Tumor Texture Indices in PET: A Comparison Between Visual Assessment and Index Values in Simulated and Patient Data
Fanny Orlhac et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Tocilizumab (Actemra)
Martin Sheppard et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
89Zr-Immuno-Positron Emission Tomography in Oncology: State-of the-Art 89Zr Radiochemistry
Sandra Heskamp et al.
BIOCONJUGATE CHEMISTRY (2017)
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
Yvonne W. S. Jauw et al.
FRONTIERS IN PHARMACOLOGY (2016)
Evaluation of 89Zr-pertuzumab in Breast Cancer Xenografts
Bernadette V. Marquez et al.
MOLECULAR PHARMACEUTICS (2014)
False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay
Keguan Chen et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2013)
Development of a Novel Long-Lived ImmunoPET Tracer for Monitoring Lymphoma Therapy in a Humanized Transgenic Mouse Model
Arutselvan Natarajan et al.
BIOCONJUGATE CHEMISTRY (2012)
In vitro and in vivo pre-clinical analysis of a F(ab')(2) fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers
Karen J. Wong et al.
EJNMMI RESEARCH (2011)
p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging
Lars R. Perk et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine
Maria J. W. D. Vosjan et al.
NATURE PROTOCOLS (2010)
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
Stephen A. Beers et al.
SEMINARS IN HEMATOLOGY (2010)
Antibody Vectors for Imaging
Tove Olafsen et al.
SEMINARS IN NUCLEAR MEDICINE (2010)
Immuno-PET: A navigator in monoclonal antibody development and applications
Guus A. M. S. van Dongen et al.
ONCOLOGIST (2007)
分享论文
